IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel ...
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) today announced that it has received notice that Medtronic has filed a complaint with the U.S. International Trade Commission (ITC), along ...
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable rechargeable sacral neuromodulation (“SNM”) devices for ...
Boston Scientific’s proposed $3.7 billion acquisition of medical device maker Axonics Inc. will likely be scrutinized by the US Federal Trade Commission because the companies are the dominant ...
Axonics Modulation Technologies got itself a $32.6 million Series A funding round that will help advance its implantable neuromodulation technology into human clinical studies to treat a variety of ...
ARTISAN‑SNM (McCrery 2019 and Lane 2020; n=129 patients), which included 19 centres in the US and Europe (the Netherlands, Belgium, France and the UK) and had a follow up of 12 months. RELAX‑OAB (Blok ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results